2026 ICD-10-CM Diagnosis Code T44.3X5AAdverse effect of other parasympatholytics [anticholinergics and antimuscarinics] and spasmolytics, initial encounter

ICD-10-CM CodesS00–T88T36-T50T44

ICD-10-CM T44.3X5A
CMSSource: CMS FY 2026 ICD-10-CM dataset · Effective Oct 1, 2025 – Sep 30, 2026

T44.3X5A is a billable ICD-10-CM diagnosis code for adverse effect of other parasympatholytics [anticholinergics and antimuscarinics] and spasmolytics, initial encounter. The 7th character A marks it as an initial encounter code, used while the patient is receiving active treatment. It is valid on HIPAA claims for fiscal year 2026 (October 1, 2025 through September 30, 2026) and groups to MS-DRG 917 through 918. The code is not accepted as a principal diagnosis by the Medicare Code Editor. In AHRQ's Clinical Classifications Software (CCSR), this diagnosis falls under Adverse effects of drugs and medicaments, initial encounter.

Code Identity

ICD-10-CM Code
T44.3X5A
Billable Status
Yes — Valid for Submission
Code Describes
Adverse effect of other parasympatholytics [anticholinergics and antimuscarinics] and spasmolytics, initial encounter
Short Description
Adverse effect of parasympatholytics and spasmolytics, init
Parent Code
Adverse effect of other parasympatholytics [anticholinergics and antimuscarinics] and spasmolytics

Code Classification

ChapterS00–T88Injury, poisoning and certain other consequences of external causes
SectionT36-T50Poisoning by, adverse effect of and underdosing of drugs, medicaments and biological substances
CategoryT44Poisoning by, adverse effect of and underdosing of drugs primarily affecting the autonomic nervous system
This CodeT44.3X5AAdverse effect of other parasympatholytics [anticholinergics and antimuscarinics] and spasmolytics, initial encounter

Code EditsBilling

Medicare Code Editor checks that affect claim validity for T44.3X5A.

There are selected codes that describe a circumstance which influences an individual's health status but not a current illness or injury, or codes that are not specific manifestations but may be due to an underlying cause. These codes are considered unacceptable as a principal diagnosis.

Approximate SynonymsGuidance

Alternate terms and clinical phrases that map to this code.

  • Adverse reaction to adiphenine
  • Adverse reaction to piperidolate
  • Adverse reaction to smooth muscle relaxant
  • Alverine adverse reaction
  • Anticholinergic adverse reaction
  • Antimuscarinic adverse reaction
  • Atropine adverse reaction
  • Belladonna alkaloids adverse reaction
  • Biperiden adverse reaction
  • Cyclopentolate adverse reaction
  • Dicycloverine adverse reaction
  • Emepronium bromide adverse reaction
  • Flavoxate adverse reaction
  • Glycopyrronium adverse reaction
  • Homatropine adverse reaction
  • Hyoscine adverse reaction
  • Hyoscine butylbromide adverse reaction
  • Hyoscine hydrobromide adverse reaction
  • Mebeverine adverse reaction
  • Mepenzolate adverse reaction
  • Methixene adverse reaction
  • Opium alkaloid adverse reaction
  • Oxybutynin adverse reaction
  • Papaverine adverse reaction
  • Phosphodiesterase inhibitor adverse reaction
  • Pipenzolate adverse reaction
  • Poldine adverse reaction
  • Procyclidine adverse reaction
  • Propantheline adverse reaction
  • Trihexyphenidyl adverse reaction
  • Tropicamide adverse reaction

Coding GuidelinesGuidance

When coding an adverse effect of a drug that has been correctly prescribed and properly administered, assign the appropriate code for the nature of the adverse effect followed by the appropriate code for the adverse effect of the drug.

The appropriate 7th character is to be added to each code from block Poisoning by, adverse effect of and underdosing of drugs primarily affecting the autonomic nervous system (T44). Use the following options for the applicable episode of care:

  • A - initial encounter
  • D - subsequent encounter
  • S - sequela

Source: ICD-10-CM Official Guidelines for Coding and Reporting, FY 2026, published by CMS and the National Center for Health Statistics.

Clinical ClassificationClinical

AHRQ’s CCSR groups this code into broader clinical categories.

CCSR INJ028
Adverse effects of drugs and medicaments, initial encounter
Default principal diagnosis: inpatient No · outpatient Yes

Clinical InformationClinical

  • Atropine

    an alkaloid, originally from atropa belladonna, but found in other plants, mainly solanaceae. hyoscyamine is the 3(s)-endo isomer of atropine.
  • Atropine Derivatives

    analogs and derivatives of atropine.
  • Hyoscyamine

    the 3(s)-endo isomer of atropine.
  • Benactyzine

    a centrally acting muscarinic antagonist. benactyzine has been used in the treatment of depression and is used in research to investigate the role of cholinergic systems on behavior.
  • Benztropine

    a centrally active muscarinic antagonist that has been used in the symptomatic treatment of parkinson disease. benztropine also inhibits the uptake of dopamine.
  • Biperiden

    a muscarinic antagonist that has effects in both the central and peripheral nervous systems. it has been used in the treatment of arteriosclerotic, idiopathic, and postencephalitic parkinsonism. it has also been used to alleviate extrapyramidal symptoms induced by phenothiazine derivatives and reserpine.
  • Cyclopentolate

    a parasympatholytic anticholinergic used solely to obtain mydriasis or cycloplegia.
  • Dexetimide

    a muscarinic antagonist that has been used to treat neuroleptic-induced parkinsonism. benzetimide is the (-)-enantimorph of dexetimide.
  • Dicyclomine

    a muscarinic antagonist used as an antispasmodic and in urinary incontinence. it has little effect on glandular secretion or the cardiovascular system. it does have some local anesthetic properties and is used in gastrointestinal, biliary, and urinary tract spasms.
  • Dyphylline

    a theophylline derivative with broncho- and vasodilator properties. it is used in the treatment of asthma, cardiac dyspnea, and bronchitis.
  • Flavoxate

    a drug that has been used in various urinary syndromes and as an antispasmodic. its therapeutic usefulness and its mechanism of action are not clear. it may have local anesthetic activity and direct relaxing effects on smooth muscle as well as some activity as a muscarinic antagonist.
  • Gefarnate

    a water insoluble terpene fatty acid used in the treatment of gastrointestinal ulcers; it facilitates the healing and function of mucosal tissue.
  • Glycopyrrolate

    a muscarinic antagonist used as an antispasmodic, in some disorders of the gastrointestinal tract, and to reduce salivation with some anesthetics.
  • Hyoscyamus

    a plant genus of the family solanaceae which contains tropanes.
  • Methantheline

    a quaternary ammonium compound that acts as an antimuscarinic agent. it has been used in the treatment of peptic ulcer, in gastrointestinal disorders associated with smooth muscle spasm, and in the management of urinary incontinence, and may also be used for the treatment of hyperhidrosis.
  • Papaverine

    an alkaloid found in opium but not closely related to the other opium alkaloids in its structure or pharmacological actions. it is a direct-acting smooth muscle relaxant used in the treatment of impotence and as a vasodilator, especially for cerebral vasodilation. the mechanism of its pharmacological actions is not clear, but it apparently can inhibit phosphodiesterases and it may have direct actions on calcium channels.
  • Procyclidine

    a muscarinic antagonist that crosses the blood-brain barrier and is used in the treatment of drug-induced extrapyramidal disorders and in parkinsonism.
  • Propantheline

    a muscarinic antagonist used as an antispasmodic, in rhinitis, in urinary incontinence, and in the treatment of ulcers. at high doses it has nicotinic effects resulting in neuromuscular blocking.
  • Butylscopolammonium Bromide

    antimuscarinic quaternary ammonium derivative of scopolamine used to treat cramps in gastrointestinal, urinary, uterine, and biliary tracts, and to facilitate radiologic visualization of the gastrointestinal tract.
  • N-Methylscopolamine

    a muscarinic antagonist used to study binding characteristics of muscarinic cholinergic receptors.
  • Scopolamine

    an alkaloid from solanaceae, especially datura and scopolia. scopolamine and its quaternary derivatives act as antimuscarinics like atropine, but may have more central nervous system effects. its many uses include an anesthetic premedication, the treatment of urinary incontinence and motion sickness, an antispasmodic, and a mydriatic and cycloplegic.
  • Scopolamine Derivatives

    analogs or derivatives of scopolamine.
  • Tolperisone

    a centrally acting muscle relaxant that has been used for the symptomatic treatment of spasticity and muscle spasm. (from martindale, the extra pharmacopoeia, 30th ed, p1211)
  • Trihexyphenidyl

    one of the centrally acting muscarinic antagonists used for treatment of parkinsonian disorders and drug-induced extrapyramidal movement disorders and as an antispasmodic.
  • Trimebutine

    proposed spasmolytic with possible local anesthetic action used in gastrointestinal disorders.
  • Tropicamide

    one of the muscarinic antagonists with pharmacologic action similar to atropine and used mainly as an ophthalmic parasympatholytic or mydriatic.

Table of Drugs and ChemicalsClinical

Substances in the Table of Drugs and Chemicals that reference this code family. Always confirm in the Tabular List before coding.

SubstanceAccidentalSelf-harmAssaultUndeter­minedAdverse
Effect
Under­dosing
AdiphenineT44.3X1T44.3X2T44.3X3T44.3X4T44.3X5T44.3X6
AlverineT44.3X1T44.3X2T44.3X3T44.3X4T44.3X5T44.3X6
Ambutonium bromideT44.3X1T44.3X2T44.3X3T44.3X4T44.3X5T44.3X6
AminopentamideT44.3X1T44.3X2T44.3X3T44.3X4T44.3X5T44.3X6
AmprotropineT44.3X1T44.3X2T44.3X3T44.3X4T44.3X5T44.3X6
AniscoropineT44.3X1T44.3X2T44.3X3T44.3X4T44.3X5T44.3X6
Anisotropine methyl-bromideT44.3X1T44.3X2T44.3X3T44.3X4T44.3X5T44.3X6
Anticholinergic NECT44.3X1T44.3X2T44.3X3T44.3X4T44.3X5T44.3X6
Antimuscarinic NECT44.3X1T44.3X2T44.3X3T44.3X4T44.3X5T44.3X6
ArtaneT44.3X1T44.3X2T44.3X3T44.3X4T44.3X5T44.3X6
AtropineT44.3X1T44.3X2T44.3X3T44.3X4T44.3X5T44.3X6
Atropine::derivativeT44.3X1T44.3X2T44.3X3T44.3X4T44.3X5T44.3X6
Atropine::methonitrateT44.3X1T44.3X2T44.3X3T44.3X4T44.3X5T44.3X6
Belladonna [See Also: Nightshade]T44.3X1T44.3X2T44.3X3T44.3X4T44.3X5T44.3X6
Belladonna [See Also: Nightshade]::alkaloidsT44.3X1T44.3X2T44.3X3T44.3X4T44.3X5T44.3X6
Belladonna [See Also: Nightshade]::extractT44.3X1T44.3X2T44.3X3T44.3X4T44.3X5T44.3X6
Belladonna [See Also: Nightshade]::herbT44.3X1T44.3X2T44.3X3T44.3X4T44.3X5T44.3X6
BenactyzineT44.3X1T44.3X2T44.3X3T44.3X4T44.3X5T44.3X6
BenaprizineT44.3X1T44.3X2T44.3X3T44.3X4T44.3X5T44.3X6
BenzhexolT44.3X1T44.3X2T44.3X3T44.3X4T44.3X5T44.3X6
Benzilonium bromideT44.3X1T44.3X2T44.3X3T44.3X4T44.3X5T44.3X6
BenztropineT44.3X1T44.3X2T44.3X3T44.3X4T44.3X5T44.3X6
Benztropine::anticholinergicT44.3X1T44.3X2T44.3X3T44.3X4T44.3X5T44.3X6
Benztropine::antiparkinsonT44.3X1T44.3X2T44.3X3T44.3X4T44.3X5T44.3X6
Bevonium metilsulfateT44.3X1T44.3X2T44.3X3T44.3X4T44.3X5T44.3X6
BiperidenT44.3X1T44.3X2T44.3X3T44.3X4T44.3X5T44.3X6
BornaprineT44.3X1T44.3X2T44.3X3T44.3X4T44.3X5T44.3X6
ButethamateT44.3X1T44.3X2T44.3X3T44.3X4T44.3X5T44.3X6
Butropium bromideT44.3X1T44.3X2T44.3X3T44.3X4T44.3X5T44.3X6
CamylofinT44.3X1T44.3X2T44.3X3T44.3X4T44.3X5T44.3X6
CaramiphenT44.3X1T44.3X2T44.3X3T44.3X4T44.3X5T44.3X6
Carpronium chlorideT44.3X1T44.3X2T44.3X3T44.3X4T44.3X5T44.3X6
ChlorbenzoxamineT44.3X1T44.3X2T44.3X3T44.3X4T44.3X5T44.3X6
Cimetropium bromideT44.3X1T44.3X2T44.3X3T44.3X4T44.3X5T44.3X6
Clidinium bromideT44.3X1T44.3X2T44.3X3T44.3X4T44.3X5T44.3X6
ClorotepineT44.3X1T44.3X2T44.3X3T44.3X4T44.3X5T44.3X6
CogentinT44.3X1T44.3X2T44.3X3T44.3X4T44.3X5T44.3X6
CyclodrineT44.3X1T44.3X2T44.3X3T44.3X4T44.3X5T44.3X6
CyclopentolateT44.3X1T44.3X2T44.3X3T44.3X4T44.3X5T44.3X6
CycrimineT44.3X1T44.3X2T44.3X3T44.3X4T44.3X5T44.3X6
DexetimideT44.3X1T44.3X2T44.3X3T44.3X4T44.3X5T44.3X6
Dibutoline sulfateT44.3X1T44.3X2T44.3X3T44.3X4T44.3X5T44.3X6
DicyclomineT44.3X1T44.3X2T44.3X3T44.3X4T44.3X5T44.3X6
DicycloverineT44.3X1T44.3X2T44.3X3T44.3X4T44.3X5T44.3X6
DiisopromineT44.3X1T44.3X2T44.3X3T44.3X4T44.3X5T44.3X6
DiphemanilT44.3X1T44.3X2T44.3X3T44.3X4T44.3X5T44.3X6
Diphemanil::metilsulfateT44.3X1T44.3X2T44.3X3T44.3X4T44.3X5T44.3X6
DrotaverineT44.3X1T44.3X2T44.3X3T44.3X4T44.3X5T44.3X6
DuboisineT44.3X1T44.3X2T44.3X3T44.3X4T44.3X5T44.3X6
DyphyllineT44.3X1T44.3X2T44.3X3T44.3X4T44.3X5T44.3X6
Emepronium (salts)T44.3X1T44.3X2T44.3X3T44.3X4T44.3X5T44.3X6
Emepronium (salts)::bromideT44.3X1T44.3X2T44.3X3T44.3X4T44.3X5T44.3X6
EthaverineT44.3X1T44.3X2T44.3X3T44.3X4T44.3X5T44.3X6
EthopropazineT44.3X1T44.3X2T44.3X3T44.3X4T44.3X5T44.3X6
EtomidolineT44.3X1T44.3X2T44.3X3T44.3X4T44.3X5T44.3X6
EtybenzatropineT44.3X1T44.3X2T44.3X3T44.3X4T44.3X5T44.3X6
EuphthalmineT44.3X1T44.3X2T44.3X3T44.3X4T44.3X5T44.3X6
Extrapyramidal antagonist NECT44.3X1T44.3X2T44.3X3T44.3X4T44.3X5T44.3X6
FenoverineT44.3X1T44.3X2T44.3X3T44.3X4T44.3X5T44.3X6
FlavoxateT44.3X1T44.3X2T44.3X3T44.3X4T44.3X5T44.3X6
FlopropioneT44.3X1T44.3X2T44.3X3T44.3X4T44.3X5T44.3X6
GefarnateT44.3X1T44.3X2T44.3X3T44.3X4T44.3X5T44.3X6
GlycopyrrolateT44.3X1T44.3X2T44.3X3T44.3X4T44.3X5T44.3X6
GlycopyrroniumT44.3X1T44.3X2T44.3X3T44.3X4T44.3X5T44.3X6
Glycopyrronium::bromideT44.3X1T44.3X2T44.3X3T44.3X4T44.3X5T44.3X6
Hexasonium iodideT44.3X1T44.3X2T44.3X3T44.3X4T44.3X5T44.3X6
HexocycliumT44.3X1T44.3X2T44.3X3T44.3X4T44.3X5T44.3X6
Hexocyclium::metilsulfateT44.3X1T44.3X2T44.3X3T44.3X4T44.3X5T44.3X6
HomatropineT44.3X1T44.3X2T44.3X3T44.3X4T44.3X5T44.3X6
Homatropine::methylbromideT44.3X1T44.3X2T44.3X3T44.3X4T44.3X5T44.3X6
HyoscineT44.3X1T44.3X2T44.3X3T44.3X4T44.3X5T44.3X6
HyoscyamineT44.3X1T44.3X2T44.3X3T44.3X4T44.3X5T44.3X6
HyoscyamusT44.3X1T44.3X2T44.3X3T44.3X4T44.3X5T44.3X6
Hyoscyamus::dry extractT44.3X1T44.3X2T44.3X3T44.3X4T44.3X5T44.3X6
IsomethepteneT44.3X1T44.3X2T44.3X3T44.3X4T44.3X5T44.3X6
IsopropamideT44.3X1T44.3X2T44.3X3T44.3X4T44.3X5T44.3X6
Isopropamide::iodideT44.3X1T44.3X2T44.3X3T44.3X4T44.3X5T44.3X6
LevsinT44.3X1T44.3X2T44.3X3T44.3X4T44.3X5T44.3X6
MebeverineT44.3X1T44.3X2T44.3X3T44.3X4T44.3X5T44.3X6
MeladrazineT44.3X1T44.3X2T44.3X3T44.3X4T44.3X5T44.3X6
MepenzolateT44.3X1T44.3X2T44.3X3T44.3X4T44.3X5T44.3X6
Mepenzolate::bromideT44.3X1T44.3X2T44.3X3T44.3X4T44.3X5T44.3X6
MepiperphenidolT44.3X1T44.3X2T44.3X3T44.3X4T44.3X5T44.3X6
MethanthelineT44.3X1T44.3X2T44.3X3T44.3X4T44.3X5T44.3X6
Methanthelinium bromideT44.3X1T44.3X2T44.3X3T44.3X4T44.3X5T44.3X6
MethixeneT44.3X1T44.3X2T44.3X3T44.3X4T44.3X5T44.3X6
Methscopolamine bromideT44.3X1T44.3X2T44.3X3T44.3X4T44.3X5T44.3X6
Methylatropine nitrateT44.3X1T44.3X2T44.3X3T44.3X4T44.3X5T44.3X6
Methylbenactyzium bromideT44.3X1T44.3X2T44.3X3T44.3X4T44.3X5T44.3X6
MetixeneT44.3X1T44.3X2T44.3X3T44.3X4T44.3X5T44.3X6
MilverineT44.3X1T44.3X2T44.3X3T44.3X4T44.3X5T44.3X6
MoxaverineT44.3X1T44.3X2T44.3X3T44.3X4T44.3X5T44.3X6
MydriacylT44.3X1T44.3X2T44.3X3T44.3X4T44.3X5T44.3X6
Octatropine methyl-bromideT44.3X1T44.3X2T44.3X3T44.3X4T44.3X5T44.3X6
Otilonium bromideT44.3X1T44.3X2T44.3X3T44.3X4T44.3X5T44.3X6
Oxapium iodideT44.3X1T44.3X2T44.3X3T44.3X4T44.3X5T44.3X6
OxybutyninT44.3X1T44.3X2T44.3X3T44.3X4T44.3X5T44.3X6
OxyphencyclimineT44.3X1T44.3X2T44.3X3T44.3X4T44.3X5T44.3X6
Oxyphenonium bromideT44.3X1T44.3X2T44.3X3T44.3X4T44.3X5T44.3X6
PapaverineT44.3X1T44.3X2T44.3X3T44.3X4T44.3X5T44.3X6
Parasympatholytic NECT44.3X1T44.3X2T44.3X3T44.3X4T44.3X5T44.3X6
Penthienate bromideT44.3X1T44.3X2T44.3X3T44.3X4T44.3X5T44.3X6
PhenglutarimideT44.3X1T44.3X2T44.3X3T44.3X4T44.3X5T44.3X6
Pinaverium bromideT44.3X1T44.3X2T44.3X3T44.3X4T44.3X5T44.3X6
Pipenzolate bromideT44.3X1T44.3X2T44.3X3T44.3X4T44.3X5T44.3X6
PiperidolateT44.3X1T44.3X2T44.3X3T44.3X4T44.3X5T44.3X6
PipethanateT44.3X1T44.3X2T44.3X3T44.3X4T44.3X5T44.3X6
Poldine metilsulfateT44.3X1T44.3X2T44.3X3T44.3X4T44.3X5T44.3X6
PramiverineT44.3X1T44.3X2T44.3X3T44.3X4T44.3X5T44.3X6
PridinolT44.3X1T44.3X2T44.3X3T44.3X4T44.3X5T44.3X6
Prifinium bromideT44.3X1T44.3X2T44.3X3T44.3X4T44.3X5T44.3X6
Pro-BanthineT44.3X1T44.3X2T44.3X3T44.3X4T44.3X5T44.3X6
ProcyclidineT44.3X1T44.3X2T44.3X3T44.3X4T44.3X5T44.3X6
ProfenamineT44.3X1T44.3X2T44.3X3T44.3X4T44.3X5T44.3X6
ProfenilT44.3X1T44.3X2T44.3X3T44.3X4T44.3X5T44.3X6
PropanthelineT44.3X1T44.3X2T44.3X3T44.3X4T44.3X5T44.3X6
Propantheline::bromideT44.3X1T44.3X2T44.3X3T44.3X4T44.3X5T44.3X6
RociverineT44.3X1T44.3X2T44.3X3T44.3X4T44.3X5T44.3X6
ScopolamineT44.3X1T44.3X2T44.3X3T44.3X4T44.3X5T44.3X6
Scopolia extractT44.3X1T44.3X2T44.3X3T44.3X4T44.3X5T44.3X6
Smooth muscle relaxantT44.3X1T44.3X2T44.3X3T44.3X4T44.3X5T44.3X6
SpacolineT44.3X1T44.3X2T44.3X3T44.3X4T44.3X5T44.3X6
SpasmolyticT44.3X1T44.3X2T44.3X3T44.3X4T44.3X5T44.3X6
Spasmolytic::anticholinergicsT44.3X1T44.3X2T44.3X3T44.3X4T44.3X5T44.3X6
Spasmolytic::autonomicT44.3X1T44.3X2T44.3X3T44.3X4T44.3X5T44.3X6
Spasmolytic::bronchial NECT44.3X1T44.3X2T44.3X3T44.3X4T44.3X5T44.3X6
Spasmolytic::quaternary ammoniumT44.3X1T44.3X2T44.3X3T44.3X4T44.3X5T44.3X6
Spasmolytic::skeletal muscle NECT44.3X1T44.3X2T44.3X3T44.3X4T44.3X5T44.3X6
SulmetozineT44.3X1T44.3X2T44.3X3T44.3X4T44.3X5T44.3X6
ThiphenamilT44.3X1T44.3X2T44.3X3T44.3X4T44.3X5T44.3X6
TiemoniumT44.3X1T44.3X2T44.3X3T44.3X4T44.3X5T44.3X6
Tiemonium::iodideT44.3X1T44.3X2T44.3X3T44.3X4T44.3X5T44.3X6
TifenamilT44.3X1T44.3X2T44.3X3T44.3X4T44.3X5T44.3X6
TigloidineT44.3X1T44.3X2T44.3X3T44.3X4T44.3X5T44.3X6
Timepidium bromideT44.3X1T44.3X2T44.3X3T44.3X4T44.3X5T44.3X6
Tiquizium bromideT44.3X1T44.3X2T44.3X3T44.3X4T44.3X5T44.3X6
TolperisoneT44.3X1T44.3X2T44.3X3T44.3X4T44.3X5T44.3X6
ToquizineT44.3X1T44.3X2T44.3X3T44.3X4T44.3X5T44.3X6
TrasentineT44.3X1T44.3X2T44.3X3T44.3X4T44.3X5T44.3X6
TriampyzineT44.3X1T44.3X2T44.3X3T44.3X4T44.3X5T44.3X6
Tricyclamol chlorideT44.3X1T44.3X2T44.3X3T44.3X4T44.3X5T44.3X6
Tridihexethyl iodideT44.3X1T44.3X2T44.3X3T44.3X4T44.3X5T44.3X6
TrihexyphenidylT44.3X1T44.3X2T44.3X3T44.3X4T44.3X5T44.3X6
TrimebutineT44.3X1T44.3X2T44.3X3T44.3X4T44.3X5T44.3X6
Trimeprazine (tartrate)T44.3X1T44.3X2T44.3X3T44.3X4T44.3X5T44.3X6
TriperidenT44.3X1T44.3X2T44.3X3T44.3X4T44.3X5T44.3X6
TrithiozineT44.3X1T44.3X2T44.3X3T44.3X4T44.3X5T44.3X6
TritiozineT44.3X1T44.3X2T44.3X3T44.3X4T44.3X5T44.3X6
TropacineT44.3X1T44.3X2T44.3X3T44.3X4T44.3X5T44.3X6
TropatepineT44.3X1T44.3X2T44.3X3T44.3X4T44.3X5T44.3X6
TropicamideT44.3X1T44.3X2T44.3X3T44.3X4T44.3X5T44.3X6
Trospium chlorideT44.3X1T44.3X2T44.3X3T44.3X4T44.3X5T44.3X6
Valethamate bromideT44.3X1T44.3X2T44.3X3T44.3X4T44.3X5T44.3X6

Patient EducationClinical

Drug Reactions

Most of the time, medicines make our lives better. They reduce aches and pains, fight infections, and control problems such as high blood pressure or diabetes. But medicines can also cause unwanted reactions, such as drug interactions, side effects, and allergies.

The full article covers:

  • What is a drug interaction?
  • What are side effects?
  • What are drug allergies?
  • How can I stay safe when taking medicines?

Read the full article at MedlinePlus

Courtesy of MedlinePlus, a service of the U.S. National Library of Medicine.

Convert T44.3X5A to ICD-9-CMHistory

The closest ICD-9-CM equivalents under the General Equivalence Mappings.

ICD-9-CM
995.29 Adv eff med/biol NEC/NOS
ApproximateCombination The match is approximate, and more than one code can be needed to describe the source diagnosis. Confirm with contextual judgment.
ICD-9-CM
E941.1 Adv eff parasympatholytc
ApproximateCombination The match is approximate, and more than one code can be needed to describe the source diagnosis. Confirm with contextual judgment.

Code HistoryHistory

FY 2016AddedAdded to the ICD-10-CM code setEffective October 1, 2015, the first year of ICD-10-CM.
FY 2017–2025No changes
FY 2026CurrentCurrent code set, no changesEffective October 1, 2025 through September 30, 2026.

Questions About T44.3X5AOverview

Is T44.3X5A a billable code?

Yes. This is a billable ICD-10-CM code, specific enough to report adverse effect of other parasympatholytics [anticholinergics and antimuscarinics] and spasmolytics, initial encounter on HIPAA-covered claims from October 1, 2025 through September 30, 2026.

What does the 7th character A in T44.3X5A mean?

The final character A marks the initial encounter: use it while the patient is receiving active treatment for adverse effect of other parasympatholytics [anticholinergics and antimuscarinics] and spasmolytics, such as an emergency visit or first evaluation.

What MS-DRG does T44.3X5A group to?

On inpatient claims, adverse effect of other parasympatholytics [anticholinergics and antimuscarinics] and spasmolytics, initial encounter maps to MS-DRG 917, 918, with relative weights from 0.8571 to 1.5684 depending on complications. Higher weights mean higher Medicare reimbursement.

Can T44.3X5A be a principal diagnosis?

No. The Medicare Code Editor rejects this code as a principal diagnosis because adverse effect of other parasympatholytics [anticholinergics and antimuscarinics] and spasmolytics, initial encounter describes a circumstance that influences health status rather than a current illness. Report it as a secondary diagnosis.

What is the ICD-9 equivalent of T44.3X5A?

Under the General Equivalence Mappings, adverse effect of other parasympatholytics [anticholinergics and antimuscarinics] and spasmolytics, initial encounter converts to ICD-9-CM 995.29 (adv eff med/biol NEC/NOS) and E941.1 (adv eff parasympatholytc). The mapping is approximate, so confirm the match fits the documentation.

Footnotes

[1] Not chronic - A diagnosis code that does not fit the criteria for chronic condition (duration, ongoing medical treatment, and limitations) is considered not chronic. Some codes designated as not chronic are acute conditions. Other diagnosis codes that indicate a possible chronic condition, but for which the duration of the illness is not specified in the code description (i.e., we do not know the condition has lasted 12 months or longer) also are considered not chronic.